Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Osteoporosis International
Published in: Osteoporosis International 3/2011

01-03-2011 | Original Article

Cost-effectiveness of bazedoxifene incorporating the FRAX® algorithm in a European perspective

Authors: F. Borgström, O. Ström, M. Kleman, E. McCloskey, H. Johansson, A. Odén, J. A. Kanis

Published in: Osteoporosis International | Issue 3/2011

Login to get access

Abstract

Summary

The cost-effectiveness of bazedoxifene was compared to placebo in France, Germany, Italy, Spain, Sweden and the UK from a healthcare perspective using FRAX® for both fracture risks and for treatment efficacy. Cost/QALY differences were explained to a large extent by differences in fracture risk.

Introduction

In cost-effectiveness modelling of osteoporosis treatments, the fracture risk has traditionally been calculated with risk adjustments based on age, bone mineral density and prior fracture. However, knowledge of additional clinical risk factors contributes to fracture risk assessment as demonstrated by the FRAX® tool. Bazedoxifene, a new selective estrogen receptor modulator for the treatment and prevention of osteoporosis, has been shown in a phase III clinical trial to reduce the risk of osteoporotic fractures in women. In an analysis using FRAX®, the efficacy of bazedoxifene was greater in patients with higher fracture risk.

Methods

The aim of this study was to evaluate the cost-effectiveness of bazedoxifene compared to placebo in France, Germany, Italy, Spain, Sweden and the UK from a healthcare perspective using FRAX®. A Markov cohort model was adapted to incorporate the FRAX® risk factors. FRAX® produces relative risks for hip fractures and major osteoporotic fractures. Patients were given a 5-year intervention, reducing the risk of fractures in a risk-dependent manner. The effect of treatment on fractures was assumed to decline linearly over 5 years after the intervention.

Results

There are large cost/quality-adjusted life year variations between countries in the European setting studied. The base case values ranged from cost saving (Sweden) to EUR 105,450 (Spain) in 70-year-old women with a T-score of −2.5 SD and a prior fracture.

Conclusion

Bazedoxifene can be a cost-effective treatment for postmenopausal osteoporosis. The variability between countries was explained to a large extent by differences in fracture risk, and the estimated cost-effectiveness was highly dependent on the population’s FRAX®-estimated probability of major osteoporotic fracture.
Literature
1.
Cooper C, Atkinson EJ, Jacobsen SJ, O’Fallon WM, Melton LJ 3rd (1993) Population-based study of survival after osteoporotic fractures. Am J Epidemiol 137:1001–1005PubMed
2.
Silverman SL, Christiansen C, Genant HK, Vukicevic S, Zanchetta JR, de Villiers TJ, Constantine GD, Chines AA (2008) Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial. J Bone Miner Res 23:1923–1934CrossRefPubMed
3.
McCloskey E, Johansson H, Oden A, Kanis JA (2009) Bazedoxifene reduces all clinical fractures and morphometric vertebral fractures in postmenopausal women at increased fracture risk assessed with FRAX®. Osteoporos Int 20(Suppl 2):199–200
4.
Kanis JA, Johansson H, Oden A, McCloskey EV (2009) Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX. Bone 44:1049–1054CrossRefPubMed
5.
Strom O, Borgstrom F, Sen SS, Boonen S, Haentjens P, Johnell O, Kanis JA (2007) Cost-effectiveness of alendronate in the treatment of postmenopausal women in 9 European countries—an economic evaluation based on the fracture intervention trial. Osteoporos Int 18:1047–1061CrossRefPubMed
6.
Ström O, Coelho J, Borgstrom F, McCloskey E, Odén A, Johansson H, Kanis J (2009) Cost-effectiveness of bazedoxifene in the UK and Sweden incorporating the FRAX-algorithm Oral presentation (OC27). ECCEO, Athens
7.
Borgstrom F, Zethraeus N (2003) Economic assessment based on a clinical study of risedronate. Fracture prevention in elderly women with osteoporosis is cost-effective. Lakartidningen 100:36–40PubMed
8.
Borgstrom F, Johnell O, Kanis JA, Oden A, Sykes D, Jonsson B (2004) Cost effectiveness of raloxifene in the treatment of osteoporosis in Sweden: an economic evaluation based on the MORE study. Pharmacoeconomics 22:1153–1165CrossRefPubMed
9.
Kanis JA, Borgstrom F, Johnell O, Oden A, Sykes D, Jonsson B (2005) Cost-effectiveness of raloxifene in the UK: an economic evaluation based on the MORE study. Osteoporos Int 16:15–25CrossRefPubMed
10.
Borgstrom F, Zethraeus N, Johnell O, Lidgren L, Ponzer S, Svensson O, Abdon P, Ornstein E, Lunsjo K, Thorngren KG, Sernbo I, Rehnberg C, Jonsson B (2006) Costs and quality of life associated with osteoporosis-related fractures in Sweden. Osteoporos Int 17:637–650CrossRefPubMed
11.
Ström O, Borgstrom F, Zethraeus N, Johnell O, Lidgren L, Ponzer S, Svensson O, Abdon P, Ornstein E, Ceder L, Thorngren KG, Sernbo I, Jonsson B (2008) Long-term cost and effect on quality of life of osteoporosis-related fractures in Sweden. Acta Orthop 79:269–280CrossRefPubMed
12.
Kanis JA, Johnell O, Oden A, Jonsson B, Dawson A, Dere W (2000) Risk of hip fracture derived from relative risks: an analysis applied to the population of Sweden. Osteoporos Int 11:120–127CrossRefPubMed
13.
De Laet CE, van Hout BA, Burger H, Hofman A, Pols HA (1997) Bone density and risk of hip fracture in men and women: cross sectional analysis. Br Med J 315:221–225
14.
Kanis JA, Johansson H, Oden A, McCloskey EV (2009) Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX((R)). Bone 44:1049–1054
15.
McCloskey E, Johansson H, Oden A, Kanis J (2009) Bazedoxifen reduces all clinical fractures and morphometric vertebral fractures in postmenopausal women at increased fracture risk assessed with FRAX®. Oral presentation (OC32), ECCEO, Athens
16.
EMEA (2009) Committee for medicinal products for human use—summary of positive opinion for Conbriza. London, 19 February
17.
Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756–765CrossRefPubMed
18.
Black DM, Thompson DE, Bauer DC, Ensrud K, Musliner T, Hochberg MC, Nevitt MC, Suryawanshi S, Cummings SR (2000) Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab 85:4118–4124CrossRefPubMed
19.
Huybrechts KF, Ishak KJ, Caro JJ (2006) Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone 38:922–928CrossRefPubMed
20.
Seeman E, Compston J, Adachi J, Brandi ML, Cooper C, Dawson-Hughes B, Jonsson B, Pols H, Cramer JA (2007) Non-compliance: the Achilles’ heel of anti-fracture efficacy. Osteoporos Int 18:711–719CrossRefPubMed
21.
(2008) Final appraisal determination. Alendronate, etidronate, risedronate, raloxifene, and strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women. National Institute for Health and Clinical Excellence, London.
22.
(2008) Final appraisal determination. Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women. National Institute for Health and Clinical Excellence, London.
23.
Kanis JA, Brazier JE, Stevenson M, Calvert NW, Lloyd Jones M (2002) Treatment of established osteoporosis: a systematic review and cost-utility analysis. Health Technol Assess 6:1–146PubMed
24.
Elffors I, Allander E, Kanis JA, Gullberg B, Johnell O, Dequeker J, Dilsen G, Gennari C, Lopes Vaz AA, Lyritis G et al (1994) The variable incidence of hip fracture in southern Europe: the MEDOS Study. Osteoporos Int 4:253–263CrossRefPubMed
25.
Brecht JG, Kruse HP, Mohrke W, Oestreich A, Huppertz E (2004) Health-economic comparison of three recommended drugs for the treatment of osteoporosis. Int J Clin Pharmacol Res 24:1–10PubMed
26.
Singer BR, McLauchlan GJ, Robinson CM, Christie J (1998) Epidemiology of fractures in 15,000 adults: the influence of age and gender. J Bone Joint Surg Br 80:243–248CrossRefPubMed
27.
Kanis JA, Johnell O, Oden A, Sembo I, Redlund-Johnell I, Dawson A, De Laet C, Jonsson B (2000) Long-term risk of osteoporotic fracture in Malmo. Osteoporos Int 11:669–674CrossRefPubMed
28.
Kanis JA, Oden A, Johnell O, Jonsson B, de Laet C, Dawson A (2001) The burden of osteoporotic fractures: a method for setting intervention thresholds. Osteoporos Int 12:417–427CrossRefPubMed
29.
Silverstein MD, Heit JA, Mohr DN, Petterson TM, O’Fallon WM, Melton LJ 3rd (1998) Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med 158:585–593CrossRefPubMed
30.
Centre for Epidemiology at the National Board of Health and Welfare, Sweden.
31.
Kanis JA, Johnell O, Oden A, Johansson H, McCloskey E (2008) FRAXTM and the assessment of fracture probability in men and women from the UK. Osteoporos Int 19:385–397CrossRefPubMed
32.
Lothgren M, Zethraeus N (2000) Definition, interpretation and calculation of cost-effectiveness acceptability curves. Health Econ 9:623–630CrossRefPubMed
33.
Jonsson B, Christiansen C, Johnell O, Hedbrandt J, Karlsson G (1996) Cost-effectiveness of fracture prevention in established osteoporosis. Scand J Rheumatol Suppl 103:30–38CrossRefPubMed
34.
Borgstrom F, Carlsson A, Sintonen H, Boonen S, Haentjens P, Burge R, Johnell O, Jonsson B, Kanis JA (2006) The cost-effectiveness of risedronate in the treatment of osteoporosis: an international perspective. Osteoporos Int 17:996–1007CrossRefPubMed
35.
Borgstrom F, Jonsson B, Strom O, Kanis JA (2006) An economic evaluation of strontium ranelate in the treatment of osteoporosis in a Swedish setting: based on the results of the SOTI and TROPOS trials. Osteoporos Int 17:1781–1793CrossRefPubMed
36.
Kind P, Dolan P, Gudex C, Williams A (1998) Variations in population health status: results from a United Kingdom national questionnaire survey. Br Med J 316:736–741
37.
Burstrom K, Johannesson M, Diderichsen F (2001) Swedish population health-related quality of life results using the EQ-5D. Qual Life Res 10:621–635CrossRefPubMed
38.
National Osteoporosis Foundation (1998). Osteoporosis: review of the evidence for prevention, diagnosis and treatment and cost-effective analysis. Osteoporos Int 8(Suppl 4):1–88.
39.
Oleksik A, Lips P, Dawson A, Minshall ME, Shen W, Cooper C, Kanis J (2000) Health-related quality of life in postmenopausal women with low BMD with or without prevalent vertebral fractures. J Bone Miner Res 15:1384–1392CrossRefPubMed
40.
Sobocki P, Lekander I, Borgstrom F, Strom O, Runeson B (2007) The economic burden of depression in Sweden from 1997 to 2005. Eur Psychiatry 22:146–152CrossRefPubMed
41.
Zethraeus N, Borgstrom F, Jonsson B, Kanis J (2005) Reassessment of the cost-effectiveness of hormone replacement therapy in Sweden: results based on the Women’s Health Initiative randomized controlled trial. Int J Technol Assess Health Care 21:433–441CrossRefPubMed
42.
Cauley JA, Thompson DE, Ensrud KC, Scott JC, Black D (2000) Risk of mortality following clinical fractures. Osteoporos Int 11:556–561CrossRefPubMed
43.
Center JR, Nguyen TV, Schneider D, Sambrook PN, Eisman JA (1999) Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 353:878–882CrossRefPubMed
44.
Bliuc D, Nguyen ND, Milch VE, Nguyen TV, Eisman JA, Center JR (2009) Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. JAMA 301:513–521CrossRefPubMed
45.
Oden A, Dawson A, Dere W, Johnell O, Jonsson B, Kanis JA (1998) Lifetime risk of hip fractures is underestimated. Osteoporos Int 8:599–603CrossRefPubMed
46.
Johnell O, Kanis JA, Oden A, Sernbo I, Redlund-Johnell I, Petterson C, De Laet C, Jonsson B (2004) Mortality after osteoporotic fractures. Osteoporos Int 15:38–42CrossRefPubMed
47.
Poor G, Atkinson EJ, O’Fallon WM, Melton LJ, 3rd (1995) Determinants of reduced survival following hip fractures in men. Clin Orthop Relat Res 260–265
48.
Kanis J, Johnell O, Odén A, Laet CD, Jonsson B, Oglesby A (2002) Excess mortality after vertebral fracture. WHO Collaborating Centre for Metabolic Bone Diseases, Sheffield, UK.
49.
Parker MJ, Anand JK (1991) What is the true mortality of hip fractures? Public Health 105:443–446CrossRefPubMed
50.
Kanis JA, Oden A, Johnell O, De Laet C, Jonsson B, Oglesby AK (2003) The components of excess mortality after hip fracture. Bone 32:468–473CrossRefPubMed
51.
52.
Vestergaard P, Rejnmark L, Mosekilde L (2007) Increased mortality in patients with a hip fracture—effect of pre-morbid conditions and post-fracture complications. Osteoporos Int 18:1583–1593CrossRefPubMed
53.
Kearon C (2003) Natural history of venous thromboembolism. Circulation 107:I22–I30PubMed
54.
Committee for medicinal products for human use (CHMP). Guidelines on the evaluation of medicinal products in the treatment of primary osteoporosis. (Lond 16 Nov 2006 CPMP/EWP/552/95 Rev.2)
55.
Kanis JA, Adams J, Borgstrom F, Cooper C, Jonsson B, Preedy D, Selby P, Compston J (2008) The cost-effectiveness of alendronate in the management of osteoporosis. Bone 42:4–15CrossRefPubMed
56.
van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C (2000) Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology (Oxford) 39:1383–1389CrossRef
57.
Kanis JA, Johansson H, Johnell O, Oden A, De Laet C, Eisman JA, Pols H, Tenenhouse A (2005) Alcohol intake as a risk factor for fracture. Osteoporos Int 16:737–742CrossRefPubMed
58.
Delmas PD, Genant HK, Crans GG, Stock JL, Wong M, Siris E, Adachi JD (2003) Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial. Bone 33:522–532CrossRefPubMed
59.
60.
Borgström F, Johnell O, Kanis J, Jönsson B, Rehnberg C (2006) At what risk is it cost-effective to treat? International intervention thresholds for the treatment of osteoporosis. Osteoporos Int 17:1459–1471
61.
Stevenson M, Davis S (2006) Analyses of the cost-effectiveness of pooled alendronate and risedronate, compared with strontium ranelate, raloxifene, etidronate and teriparatide. School of Health and Related Research, University of Sheffield. Sheffield
62.
Visentin P, Ciravegna R, Fabris F (1997) Estimating the cost per avoided hip fracture by osteoporosis treatment in Italy. Maturitas 26:185–192CrossRefPubMed
63.
Zethraeus N, Strom O, Borgstrom F (2006) What is the risk of institutionalization after hip fracture? Osteoporos Int 17(Suppl 1):57–58
64.
Gordois A, Posnett J, Borris L, Bossuyt P, Jonsson B, Levy E, de Pouvourville G (2003) The cost-effectiveness of fondaparinux compared with enoxaparin as prophylaxis against thromboembolism following major orthopedic surgery. J Thromb Haemost 1:2167–2174CrossRefPubMed
65.
Kobelt G, Berg J, Lindgren P, Izquierdo G, Sanchez-Solino O, Perez-Miranda J, Casado MA (2006) Costs and quality of life of multiple sclerosis in Spain. Eur J Health Econ 7(Suppl 2):S65–S74CrossRefPubMed
66.
67.
Strom O, Borgstrom F, Sen SS, Boonen S, Haentjens P, Johnell O, Kanis JA (2007) Cost-effectiveness of alendronate in the treatment of postmenopausal women in 9 European countries--an economic evaluation based on the fracture intervention trial. Osteoporos Int 18:1047–1061
68.
69.
Lordick F, Ehlken B, Ihbe-Heffinger A, Berger K, Krobot KJ, Pellissier J, Davies G, Deuson R (2007) Health outcomes and cost-effectiveness of aprepitant in outpatients receiving antiemetic prophylaxis for highly emetogenic chemotherapy in Germany. Eur J Cancer 43:299–307CrossRefPubMed
70.
Capri S, Perlini S (2005) Cost-effectiveness in Italy of preventive treatment with ramipril in patients at high risk of cardiovascular events. Curr Med Res Opin 21:913–921CrossRefPubMed
71.
Metadata
Title
Cost-effectiveness of bazedoxifene incorporating the FRAX® algorithm in a European perspective
Authors
F. Borgström
O. Ström
M. Kleman
E. McCloskey
H. Johansson
A. Odén
J. A. Kanis
Publication date
01-03-2011
Publisher
Springer-Verlag
Published in
Osteoporosis International / Issue 3/2011
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-010-1291-5

Other articles of this Issue 3/2011

Osteoporosis International 3/2011 Go to the issue

Original Article

Targeted intervention reduces refracture rates in patients with incident non-vertebral osteoporotic fractures: a 4-year prospective controlled study

Original Article

Reduction of whole PTH/intact PTH ratio as a predictor of bone metabolism in cinacalcet treatment of hemodialysis patients with secondary hyperparathyroidism

Case Report

Severe osteoporosis treated with teriparatide in a patient affected by recessive epidermolysis bullosa dystrophica

Original Article

Risk of femoral shaft and subtrochanteric fractures among users of bisphosphonates and raloxifene

Original Article

Guidance for the adjustment of FRAX according to the dose of glucocorticoids

Original Article

Sunlight exposure or vitamin D supplementation for vitamin D-deficient non-western immigrants: a randomized clinical trial